ReviewJournal of Cancer2024
Prostate cancer stem cells: an updated mini-review.
Review in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated Phenotypic and Transcriptomic Profiling Positions ONC212 as a Lead Imipridone in Androgen-Independent Prostate Cancer Models.International journal of molecular sciences · 2026Article
- Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.EMBO molecular medicine · 2026Article
- Prognostic biomarkers and regulatory mechanisms associated with lysine β-hydroxybutyrylation modification in prostate cancer.Frontiers in molecular biosciences · 2026Article
- Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.World journal of clinical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignant tumor in male genitourinary system. The incidence of prostate cancer ranks the first among all male malignant tumors worldwide, and the mortality rate ranks the second among all male malignant tumors. Prostate stem cells are heterogeneous subsets with the function of self-regeneration and proliferation in the prostate, which can produce all cell lineages that make up the prostate epithelium. At present, the pathogenesis of prostate cancer remains unclear. According to cancer stem cell hypothesis, prostate cancer may be a stem cell disease, which provides a new direction for revealing the pathogenesis of prostate cancer and developing treatment strategy for prostate cancer. In this mini-review, we highlight recent advances in our understanding of the origin, surface molecular markers, signaling pathway and the significance for clinical treatment of prostate cancer stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.